Evolving synergistic combinations of targeted immunotherapies to combat cancer. (Q38553010)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26205340%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

review article

1 reference

title

Evolving synergistic combinations of targeted immunotherapies to combat cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26205340%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

José Luis Pérez-Gracia

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26205340%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Ignacio Melero, MD-PhD

1

object named as

Ignacio Melero

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26205340%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

David M Berman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26205340%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

M Angela Aznar

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26205340%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Alan J Korman

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26205340%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

John Haanen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26205340%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

language of work or name

English

0 references

publication date

1 August 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26205340%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26205340%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26205340%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26205340%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

457-472

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26205340%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrc3973

20 February 2020

exact match

0 references

cites work

The immunological synapse

1 reference

The blockade of immune checkpoints in cancer immunotherapy

31 March 2020

1 reference

Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.

31 March 2020

1 reference

Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo

31 March 2020

1 reference

Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.

31 March 2020

1 reference

Immunostimulatory monoclonal antibodies for cancer therapy

31 March 2020

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

31 March 2020

1 reference

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

31 March 2020

1 reference

Cancer immunotherapy comes of age

31 March 2020

1 reference

Immune modulation in cancer with antibodies

31 March 2020

1 reference

Nivolumab plus ipilimumab in advanced melanoma

31 March 2020

1 reference

Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity

31 March 2020

1 reference

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

31 March 2020

1 reference

Radiotherapy enhances antitumor effect of anti-CD137 therapy in a mouse Glioma model

31 March 2020

1 reference

Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo

31 March 2020

1 reference

Bevacizumab plus ipilimumab in patients with metastatic melanoma

31 March 2020

1 reference

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

31 March 2020

1 reference

Mitigating the toxic effects of anticancer immunotherapy

31 March 2020

1 reference

Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells.

31 March 2020

1 reference

Orchestrating immune check-point blockade for cancer immunotherapy in combinations

31 March 2020

1 reference

Adoptive cell transfer as personalized immunotherapy for human cancer

31 March 2020

1 reference

Gene-engineered T cells for cancer therapy

31 March 2020

1 reference

Better performance of CARs deprived of the PD-1 brake

31 March 2020

1 reference

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

31 March 2020

1 reference

Anti-CTL-associated antigen 4: are regulatory T cells a target?

31 March 2020

1 reference

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

31 March 2020

1 reference

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

31 March 2020

1 reference

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

31 March 2020

1 reference

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

31 March 2020

1 reference

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

31 March 2020

1 reference

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

31 March 2020

1 reference

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

31 March 2020

1 reference

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

31 March 2020

1 reference

Restoring function in exhausted CD8 T cells during chronic viral infection

31 March 2020

1 reference

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

31 March 2020

1 reference

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer

31 March 2020

1 reference

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

31 March 2020

1 reference

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

31 March 2020

1 reference

Pembrolizumab versus Ipilimumab in Advanced Melanoma

31 March 2020

1 reference

Pembrolizumab for the treatment of non-small-cell lung cancer

31 March 2020

1 reference

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

31 March 2020

1 reference

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

31 March 2020

1 reference

Molecular signature of CD8+ T cell exhaustion during chronic viral infection.

31 March 2020

1 reference

The CD4-like molecule LAG-3, biology and therapeutic applications

31 March 2020

1 reference

Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells

31 March 2020

1 reference

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

31 March 2020

1 reference

Tim-3, a negative regulator of anti-tumor immunity

31 March 2020

1 reference

Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance.

31 March 2020

1 reference

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients

31 March 2020

1 reference

TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression

31 March 2020

1 reference

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

31 March 2020

1 reference

CEACAM1 regulates TIM-3-mediated tolerance and exhaustion

31 March 2020

1 reference

Immune regulation by 4-1BB and 4-1BBL: complexities and challenges

31 March 2020

1 reference

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

31 March 2020

1 reference

4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses

31 March 2020

1 reference

Immunotherapy of cancer with 4-1BB.

31 March 2020

1 reference

Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity

31 March 2020

1 reference

Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy

31 March 2020

1 reference

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

31 March 2020

1 reference

Targeting CD137 enhances the efficacy of cetuximab.

31 March 2020

1 reference

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

31 March 2020

1 reference

Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.

31 March 2020

1 reference

Modulation of GITR for cancer immunotherapy

31 March 2020

1 reference

CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor

31 March 2020

1 reference

Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance

31 March 2020

1 reference

Pivotal roles of CD4+ effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors

31 March 2020

1 reference

T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy

31 March 2020

1 reference

Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses

31 March 2020

1 reference

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

31 March 2020

1 reference

Science gone translational: the OX40 agonist story

31 March 2020

1 reference

OX40 is a potent immune-stimulating target in late-stage cancer patients

31 March 2020

1 reference

CD40/CD154 interactions at the interface of tolerance and immunity

31 March 2020

1 reference

Agonistic CD40 antibodies and cancer therapy

31 March 2020

1 reference

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

31 March 2020

1 reference

Role of CD27/CD70 pathway of activation in immunity and tolerance

31 March 2020

1 reference

CD27/CD70 interaction directly induces natural killer cell killing activity

31 March 2020

1 reference

CD27 Promotes Survival of Activated T Cells and Complements CD28 in Generation and Establishment of the Effector T Cell Pool

31 March 2020

1 reference

Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8+ T cell responses in the absence of CD4+ T cells

31 March 2020

1 reference

Requirement for CD70 in CD4+ Th cell-dependent and innate receptor-mediated CD8+ T cell priming

31 March 2020

1 reference

MHC class I molecules and KIRs in human history, health and survival

31 March 2020

1 reference

KIR and KIR ligand polymorphism: a new area for clinical applications?

31 March 2020

1 reference

Natural killer cell recognition of missing self

31 March 2020

1 reference

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

31 March 2020

1 reference

CD94/NKG2A inhibits NK cell activation by disrupting the actin network at the immunological synapse

31 March 2020

1 reference

The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions

31 March 2020

1 reference

Immunogenic cell death in cancer therapy

31 March 2020

1 reference

T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy

31 March 2020

1 reference

Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial

31 March 2020

1 reference

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

31 March 2020

1 reference

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

31 March 2020

1 reference

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

31 March 2020

1 reference

Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies

31 March 2020

1 reference

In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates

31 March 2020

1 reference

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

31 March 2020

1 reference

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

31 March 2020

1 reference

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

31 March 2020

1 reference

The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses

31 March 2020

1 reference

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

31 March 2020

1 reference

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

31 March 2020

1 reference

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

31 March 2020

1 reference

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.

31 March 2020

1 reference

Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity

31 March 2020

1 reference

Combination strategies for enhancing the efficacy of immunotherapy in cancer patients

31 March 2020

1 reference

Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy

31 March 2020

1 reference

Combining radiotherapy and cancer immunotherapy: a paradigm shift

31 March 2020

1 reference

Hepatotoxicity with combination of vemurafenib and ipilimumab

31 March 2020

1 reference

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

31 March 2020

1 reference

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.

31 March 2020

1 reference

The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations

31 March 2020

1 reference

Vemurafenib sensitivity skin reaction after ipilimumab

31 March 2020

1 reference

Immunologic correlates of the abscopal effect in a patient with melanoma

31 March 2020

1 reference

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.

31 March 2020

1 reference

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

31 March 2020

1 reference

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma

31 March 2020

1 reference

Management of immune-related adverse events and kinetics of response with ipilimumab

31 March 2020

1 reference

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network

31 March 2020

1 reference

Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody

31 March 2020

1 reference

Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules

31 March 2020

1 reference

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

31 March 2020

1 reference

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

31 March 2020

1 reference

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

31 March 2020

1 reference

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody

31 March 2020

1 reference

Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types

31 March 2020

1 reference

PD-1 blockade induces responses by inhibiting adaptive immune resistance

31 March 2020

1 reference

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

31 March 2020

1 reference

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab

31 March 2020

1 reference

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

31 March 2020

1 reference

A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III)

31 March 2020

1 reference

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

31 March 2020

1 reference

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma

31 March 2020

1 reference

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

31 March 2020

1 reference

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

31 March 2020

1 reference

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

31 March 2020

1 reference

The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis

31 March 2020

1 reference

Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma

31 March 2020

1 reference

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

31 March 2020

1 reference

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

31 March 2020

1 reference

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

31 March 2020

1 reference

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

31 March 2020

1 reference

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

31 March 2020

1 reference

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

31 March 2020

1 reference

An immune-active tumor microenvironment favors clinical response to ipilimumab

31 March 2020

1 reference

Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade

31 March 2020

1 reference

Identification and characterization of a tumor infiltrating CD56(+)/CD16 (-) NK cell subset with specificity for pancreatic and prostate cancer cell lines.

31 March 2020

1 reference

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

31 March 2020

1 reference

CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans

31 March 2020

1 reference

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

31 March 2020

1 reference

Selective activation of oxygen-deprived tumor-infiltrating lymphocytes through local intratumoral delivery of CD137 monoclonal antibodies

31 March 2020

1 reference

Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies

31 March 2020

1 reference

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

31 March 2020

1 reference

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer

31 March 2020

1 reference

Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.

31 March 2020

1 reference

Intratumoral immunization: a new paradigm for cancer therapy

31 March 2020

1 reference

Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects

31 March 2020

1 reference

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

31 March 2020

1 reference

PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines

31 March 2020

1 reference

Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity

31 March 2020

1 reference

Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.

31 March 2020

1 reference

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study

31 March 2020

1 reference

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

31 March 2020

1 reference

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

31 March 2020

1 reference

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

31 March 2020

1 reference

Genetic basis for clinical response to CTLA-4 blockade in melanoma

31 March 2020

1 reference

On the composition of the preimmune repertoire of T cells specific for Peptide-major histocompatibility complex ligands

31 March 2020

1 reference

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

31 March 2020

1 reference

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

31 March 2020

1 reference

Mutant MHC class II epitopes drive therapeutic immune responses to cancer

31 March 2020

1 reference

Effective tumor immunotherapy: start the engine, release the brakes, step on the gas pedal,...and get ready to face autoimmunity

31 March 2020

1 reference

12 December 2020

Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer

1 reference

12 December 2020

Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.

1 reference

12 December 2020

Characterization of the human CD27 ligand, a novel member of the TNF gene family.

1 reference

12 December 2020

Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.

1 reference

12 December 2020

Immune infiltration in human cancer: prognostic significance and disease control

1 reference

12 December 2020

Characterization of murine CD70, the ligand of the TNF receptor family member CD27.

1 reference

12 December 2020

Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation

1 reference

12 December 2020

Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC3973

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26205340%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

20 February 2020

0 references

1 reference